Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.
Frontiers4 天
Exploring the Role of Inflammation in Depression
The scientific literature has highlighted the role of inflammation in major depressive disorder (MDD), permeating several states of the disease. In chronic ...
Final proof that diet CAN help treat depression, ADHD and even serious mental illness: here ...
The phrase 'You are what you eat' derives from a pioneering French food critic who, 200 years ago, published a bestseller ...
EurekAlert!4 天
A new global study aims to map the brain signatures of bipolar disorder to transform ...
A new study, led by USC Mark and Mary Stevens Neuroimaging and Informatics Institute (Stevens INI), will explore structural ...
Neurocrine Amends Agreement With Takeda for Major Depressive Disorder Treatment
Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.
How Brain Signals Could Revolutionize Personalized Depression Treatment
Scientists at Virginia Tech are revolutionizing depression treatment by tapping into how the brain processes rewards. Their ...